Gain Therapeutics updates cash runway; expects funding into Q2 2027

Gain Therapeutics, Inc.

Cash and equivalents expected to fund operations into Q2 2027 based on current plans.
Phase 1b open-label extension completion expected in October 2026.
Phase 2 clinical study initiation planned for Q3 2026.

item 8.01

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-084086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.